608 related articles for article (PubMed ID: 17805538)
1. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
3. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Munster PN; Britten CD; Mita M; Gelmon K; Minton SE; Moulder S; Slamon DJ; Guo F; Letrent SP; Denis L; Tolcher AW
Clin Cancer Res; 2007 Feb; 13(4):1238-45. PubMed ID: 17317835
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
Zhang J; Cao J; Li J; Zhang Y; Chen Z; Peng W; Sun S; Zhao N; Wang J; Zhong D; Zhang X; Zhang J
J Hematol Oncol; 2014 Mar; 7():22. PubMed ID: 24612546
[TBL] [Abstract][Full Text] [Related]
5. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
7. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
9. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
[TBL] [Abstract][Full Text] [Related]
11. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
[TBL] [Abstract][Full Text] [Related]
12. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.
Spector NL; Robertson FC; Bacus S; Blackwell K; Smith DA; Glenn K; Cartee L; Harris J; Kimbrough CL; Gittelman M; Avisar E; Beitsch P; Koch KM
PLoS One; 2015; 10(11):e0142845. PubMed ID: 26571496
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
Lorusso PM; Adjei AA; Varterasian M; Gadgeel S; Reid J; Mitchell DY; Hanson L; DeLuca P; Bruzek L; Piens J; Asbury P; Van Becelaere K; Herrera R; Sebolt-Leopold J; Meyer MB
J Clin Oncol; 2005 Aug; 23(23):5281-93. PubMed ID: 16009947
[TBL] [Abstract][Full Text] [Related]
15. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Ranson M; Hammond LA; Ferry D; Kris M; Tullo A; Murray PI; Miller V; Averbuch S; Ochs J; Morris C; Feyereislova A; Swaisland H; Rowinsky EK
J Clin Oncol; 2002 May; 20(9):2240-50. PubMed ID: 11980995
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2
Moulder SL; Borges VF; Baetz T; Mcspadden T; Fernetich G; Murthy RK; Chavira R; Guthrie K; Barrett E; Chia SK
Clin Cancer Res; 2017 Jul; 23(14):3529-3536. PubMed ID: 28053022
[No Abstract] [Full Text] [Related]
18. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Yamamoto N; Horiike A; Fujisaka Y; Murakami H; Shimoyama T; Yamada Y; Tamura T
Cancer Chemother Pharmacol; 2008 Mar; 61(3):489-96. PubMed ID: 17483950
[TBL] [Abstract][Full Text] [Related]
20. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]